![]() "Our comprehensive support program, MyPraluent also provides important services to help patients such as disease management, and financial assistance for patients with or without insurance." "Both the Praluent 75 mg and 150 mg doses will be preferred on UnitedHealth formularies, providing physicians with the flexibility to individualize dosing for their patients," said Robert Terifay, senior vice president, commercial, Regeneron. These include approximately 8-10 million patients with either ASCVD or the inherited form of high LDL cholesterol known as HeFH. Many patients in the US face the challenge of achieving LDL cholesterol levels recommended by healthcare providers, despite treatment with standard of care including statins. "Praluent is a significant innovation for patients with the highest unmet need who may benefit from further reduction of their LDL cholesterol, and we look forward to continued collaboration with other insurers to help ensure appropriate patient access to Praluent." "We are pleased that the appropriate patients in the US now have preferred access to Praluent through UnitedHealth Group," said Jez Moulding, president, North America Pharmaceuticals, Sanofi US. The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined. ASCVD is defined as a build-up of plaque in the arteries which can lead to reduced blood flow and a number of conditions including heart attack, stroke, chest pain (stable or unstable angina), transient ischemic attack, revascularization and peripheral artery disease. Praluent, the first PCSK9 inhibitor available in the US, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Praluent is the only PCSK9 inhibitor currently available in two doses, that allows a healthcare provider to adjust the dose based on their patient's LDL cholesterol lowering needs. This decision, when combined with prior favourable coverage decisions at Express Scripts, Aetna and other insurers, provides for access to flexible dosing with Praluent on formularies covering more than 100 million patients in the United States. Praluent is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies. Sanofi, an integrated global healthcare leader, and Regeneron Pharmaceuticals, Inc., a leading science-based biopharmaceutical company, announced that UnitedHealth Group will provide preferred access to Praluent (alirocumab) injection through OptumRx and UnitedHealthcare for Commercial, Medicare, and Managed Medicaid patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |